ImmunoGen Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that abstracts highlighting two of the Company’s experimental ADC therapies, IMGN779 and IMGN632, have been accepted for presentations at the upcoming American Society of Hematology (ASH) Annual Meeting to be held December 1-4 in San Diego, California.
November 1, 2018
· 5 min read